Business Ethics in Biotechnology

🥼Business Ethics in Biotechnology Unit 14 – Biotech Ethics: Future Challenges

Biotech ethics grapples with complex issues arising from rapid scientific advances. Key concepts like autonomy, beneficence, and justice guide decision-making as we navigate the potential benefits and risks of emerging technologies. Gene editing, synthetic biology, and personalized medicine are transforming healthcare and industry. These innovations raise challenging questions about genetic engineering, data privacy, access equity, environmental impacts, and regulatory frameworks.

Key Ethical Concepts

  • Autonomy involves respecting an individual's right to make their own informed decisions about their health and body
  • Beneficence requires acting in ways that promote the wellbeing and best interests of others
    • Includes weighing potential benefits against risks when developing and deploying new biotechnologies
  • Non-maleficence obligates us to avoid causing harm to others through our actions or inaction
  • Justice demands the fair and equitable distribution of benefits and burdens across society
    • Ensures underserved populations have access to beneficial biotech advances
  • Dignity recognizes the inherent worth of all human beings regardless of their capacities or circumstances
  • Integrity in research and development maintains high standards of honesty, objectivity, and transparency
  • Stewardship of resources considers our responsibilities to use biological materials and data ethically and sustainably for the common good
  • Gene editing techniques (CRISPR) enable precise modifications to DNA sequences to alter traits or correct mutations
  • Synthetic biology constructs novel biological parts, devices, and systems or re-designs existing natural ones for useful purposes
    • Potential applications include biomanufacturing of materials, targeted therapeutics, and environmental remediation
  • Personalized medicine leverages genetic information, biomarkers, and big data analytics to tailor treatments and prevention strategies to an individual's unique profile
  • Regenerative medicine aims to replace, engineer, or regenerate human cells, tissues, or organs to restore normal function
    • Stem cell therapies and tissue engineering offer hope for treating injuries, degenerative diseases, and organ failures
  • Microbiome research explores the diverse communities of microbes living in and on the human body and their roles in health and disease
  • Nanomedicine utilizes nanoscale materials and devices for improved drug delivery, diagnostic imaging, and monitoring of physiological processes
  • Neurotechnology interfaces with the brain and nervous system to study, assess, and manipulate neural functions
    • Includes brain-computer interfaces, neural implants, and cognitive enhancement devices

Genetic Engineering Dilemmas

  • Germline editing makes heritable changes to embryos that are passed down to future generations, raising concerns about unintended consequences and the ethical limits of human intervention
  • Enhancement uses genetic engineering to boost human traits and capacities beyond the normal range, blurring the line between therapy and augmentation
    • Potential targets include intelligence, physical abilities, longevity, and emotional dispositions
  • Gene drives alter the probability that a specific allele will be transmitted to offspring, enabling the rapid spread of engineered traits through a population
    • Could be used to control disease vectors (mosquitoes) or invasive species but also poses ecological risks if unconstrained
  • Ownership and control of genetic information and engineered organisms as intellectual property raises questions of access, benefit sharing, and power dynamics
  • Safety and efficacy must be rigorously established through extensive research and clinical trials before releasing genetically modified products into the environment or using them in humans
  • Informed consent requires providing comprehensive information about the risks, benefits, and uncertainties of genetic interventions and respecting the right of individuals to make autonomous decisions
  • Public trust and engagement are essential for the responsible development and governance of genetic engineering technologies

Data Privacy and Ownership

  • Biobanks collect, store, and manage biological samples and associated data for research purposes, raising concerns about donor privacy, confidentiality, and control
  • Informed consent processes must clearly communicate how personal data will be used, shared, and protected and provide options for withdrawal or re-consent
    • Dynamic consent models allow individuals to update their preferences over time as circumstances change
  • Data sharing accelerates scientific progress by enabling collaboration and replication of findings but must be balanced against risks of re-identification or misuse
    • Anonymization techniques strip datasets of personally identifiable information before sharing to protect individual privacy
  • Commercial use of personal biodata by companies for product development, marketing, or sale to third parties poses questions of ownership, compensation, and exploitation
  • Genetic discrimination occurs when individuals are treated differently or unfairly based on their genetic characteristics by insurers, employers, or other entities
    • Legal protections (GINA in the US) prohibit certain forms of genetic discrimination but have limitations in scope and enforcement
  • Surveillance and profiling using biometric data and predictive analytics raise civil liberties concerns and can perpetuate social inequities if applied in discriminatory ways
  • Cybersecurity measures are critical to prevent unauthorized access, tampering, or theft of sensitive biodata stored in digital formats

Access and Equity Issues

  • Disparities in access to cutting-edge biotech advances and quality healthcare services can exacerbate existing health inequities along socioeconomic, racial, and geographic lines
  • High costs of development and distribution may limit the affordability and availability of new biotech products for underserved populations
    • Tiered pricing, public funding, and philanthropic partnerships can help expand access in resource-limited settings
  • Intellectual property protections (patents) incentivize innovation by granting exclusive rights to inventors but can also hinder access by maintaining high prices and restricting competition
    • Compulsory licensing allows governments to permit the production of patented products without the consent of the patent owner in situations of public health emergency or pressing societal need
  • Participatory inclusion of diverse communities in biotech research and decision-making helps ensure that their needs, values, and concerns are addressed
    • Requires proactive outreach, relationship-building, and power-sharing with marginalized groups
  • Capacity building in low-resource settings through training, infrastructure development, and technology transfer promotes self-sufficiency and sustainability
  • Global justice considers the transnational impacts of biotech policies and practices and our duties to promote health and wellbeing worldwide
    • Equitable benefit sharing, research collaborations, and solidarity in the face of common threats are key elements

Environmental Impacts

  • Biodiversity loss due to habitat destruction, pollution, climate change, and invasive species introduction poses risks to ecosystem stability and resilience
    • Biotech tools (gene drives, de-extinction) could help conserve or restore threatened species but also have unintended ecological consequences
  • Biosafety practices aim to prevent the accidental release of genetically modified organisms into the environment where they may disrupt natural systems
    • Containment measures, monitoring protocols, and emergency response plans are essential components
  • Sustainable biomanufacturing processes minimize waste, optimize resource use, and prioritize renewable feedstocks over petrochemical derivatives
    • Circular bioeconomy models recover and repurpose byproducts to reduce environmental footprint
  • Bioremediation uses living organisms (microbes, plants) to degrade, detoxify, or sequester pollutants from contaminated sites
    • Genetically engineered organisms may enhance bioremediation efficiency and specificity but raise biosafety concerns
  • Agricultural biotechnology can improve crop yields, nutritional content, and stress tolerance but also has implications for biodiversity, pesticide use, and smallholder livelihoods
    • Coexistence strategies allow for the cultivation of both genetically modified and non-modified varieties to preserve farmer autonomy and consumer choice
  • Planetary health recognizes the interdependence of human health and the health of natural systems and calls for integrated, cross-sectoral solutions to global challenges
  • One Health approaches address the connections between human, animal, and environmental health through collaborative research, policy, and practice

Regulatory Challenges

  • Precautionary principle holds that when an activity raises threats of harm to human health or the environment, precautionary measures should be taken even if some cause-and-effect relationships are not fully established scientifically
    • Shifts the burden of proof to proponents of potentially risky technologies to demonstrate safety
  • Risk-benefit analysis weighs the probability and magnitude of potential harms against the expected benefits of a technology or intervention
    • Requires robust data, clear metrics, and value judgments about acceptable levels of risk
  • Harmonization of regulatory standards across jurisdictions facilitates consistent governance, reduces barriers to trade, and promotes global cooperation
    • Divergent cultural values, political systems, and levels of development complicate efforts to achieve international consensus
  • Adaptive governance frameworks incorporate flexibility, learning, and responsiveness to changing scientific knowledge, societal concerns, and technological capabilities over time
    • Iterative cycles of assessment, deliberation, and adjustment help keep pace with rapid advancements
  • Stakeholder engagement brings together diverse perspectives (industry, academia, government, civil society) to inform the development and implementation of biotech policies
    • Helps build public trust, legitimacy, and buy-in for regulatory decisions
  • Ethical oversight mechanisms (IRBs, IACUCs) review the design and conduct of biotech research involving human or animal subjects to ensure compliance with ethical principles and guidelines
    • Challenges arise in defining and enforcing universal standards across diverse research contexts and modalities
  • Anticipatory governance aims to proactively address the ethical, legal, and social implications of emerging biotechnologies before they are widely deployed
    • Foresight methods (scenario planning, horizon scanning) can help identify potential risks and opportunities

Future Scenarios and Implications

  • Personalized medicine could transform healthcare by enabling targeted therapies, preventive interventions, and wellness optimization based on individual biomarkers and risk profiles
    • Raises questions about data privacy, algorithmic bias, and the medicalization of human diversity
  • Human enhancement technologies may expand the boundaries of physical, cognitive, and emotional capabilities, challenging notions of normalcy, authenticity, and social equality
    • Could exacerbate disparities if only accessible to the wealthy or create pressure for individuals to conform to heightened performance expectations
  • Synthetic biology has the potential to revolutionize manufacturing, energy production, and environmental remediation by harnessing the power of biological systems
    • Also poses risks of uncontrolled release, dual-use for bioweapons, and disruption of natural ecosystems
  • Regenerative medicine advances could extend the human lifespan and healthspan by repairing or replacing damaged tissues and organs
    • Prompts reflection on the meaning and value of aging, mortality, and intergenerational relationships
  • Neurotechnology interfaces may enable new forms of communication, learning, and control by directly linking brains with digital devices and AI systems
    • Threatens mental privacy, autonomy, and sense of self if misused or hacked
  • Global catastrophic biological risks (pandemics, bioterrorism, ecosystem collapse) demand proactive, coordinated, and equitable responses to mitigate harm and ensure resilience
    • Highlights the need for strengthened global health security, early warning systems, and benefit sharing
  • Inclusive futures require anticipating and addressing the needs and concerns of diverse populations, especially those historically marginalized or underserved by biotech advances
    • Calls for participatory technology assessment, community-engaged research, and cross-cultural dialogue to shape the trajectory of biotech development


© 2024 Fiveable Inc. All rights reserved.
AP® and SAT® are trademarks registered by the College Board, which is not affiliated with, and does not endorse this website.

© 2024 Fiveable Inc. All rights reserved.
AP® and SAT® are trademarks registered by the College Board, which is not affiliated with, and does not endorse this website.